|
Search
Collections
Benchmarks
Upload document
Target
CYSLTR2
Rename entity
Add alias
Merge entity
Delete entity
Embed entity
1 abstract
Abstract
Comparison of clinical outcomes of stable disease with confirmed tumor reduction and RECIST partial response for tebentafusp in metastatic uveal melanoma (mUM).
Org:
Immunocore Ltd.,
Immunocore LLC,
